中性粒细胞减少性发热

Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621-1629.

• 摘要

Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.

• 摘要

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.

• 全文
• 摘要

Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31-38.

• 全文
• 摘要

1.  Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009;144:677-685.

• 全文
• 摘要

2.  Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-1924.

• 全文
• 摘要

3.  Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621-1629.

• 摘要

4.  Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-1065.

• 摘要

5.  Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069-2076.

• 摘要

6.  Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427-437.

• 全文
• 摘要

7.  Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561-2568.

• 摘要

8.  Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.

• 摘要

9.  Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103-1110.

• 全文
• 摘要

10.  Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-4531.

• 摘要

11.  Aslani A, Smith RC, Allen BJ, et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer. 2000;88:796-803.

• 全文
• 摘要

12.  Kloess M, Wunderlich A, Trumper L, et al. Predicting hematotoxicity in multicycle chemotherapy. Blood. 1999;94:87a.

13.  Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-4311.

• 全文
• 摘要

14.  Morrison VA, Caggiano V, Fridman M, et al. A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. Proc Am Soc Clin Oncol. 2004;23:742.

15.  Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6:109-118.

• 摘要

16.  Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive Non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;37:351-360.

• 摘要

17.  Silber JH, Fridman M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol. 1998;16:2392-2400.

• 摘要

18.  Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199-3212.

• 全文
• 摘要

19.  Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-1184.

• 全文
• 摘要

20.  Kuderer NMD. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-3167.

• 摘要

21.  Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.

• 全文
• 摘要

22.  Engert A, del Giglio A, Bias P, et al. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie. 2009;32:599-604.

• 摘要

23.  Gatzemeier U, Ciuleanu T, Dediu M, et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009;4:736-740.

• 摘要

24.  de Jongh CA, Wade JC, Finley RS et al. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol. 1983;1:302-307.

• 摘要

25.  Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small cell lung cancer. J Clin Oncol. 1985;3:54-64.

• 摘要

26.  Imrie KR, Prince HM, Couture F, et al. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation. Ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant. 1995;15:267-270.

• 摘要

27.  Engles EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients. A meta-analysis. J Clin Oncol. 1998;16:1179-1187.

• 摘要

28.  Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.

• 全文
• 摘要

29.  Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988-998.

• 全文
• 摘要

30.  Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977-987.

• 全文
• 摘要

31.  Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979-995 (erratum in: Ann Intern Med. 2006;144:704).

• 摘要

32.  Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53-63.

• 摘要

33.  von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292-298.

• 全文
• 摘要

34.  Ziakas PD, Kourbeti IS, Voulgarelis M, et al. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther. 2010;32:2316-2336.

• 摘要

35.  Press OV, Ramsey PG, Larson EB, et al. Hickman catheter infections in patients with malignancies. Medicine (Baltimore). 1984;63:189-200.

• 摘要

36.  Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990;69:296-306.

• 摘要

37.  Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715-719.

• 摘要

38.  Valdivieso M, Gil-Extremera B, Zornoza J, et al. Gram-negative bacillary pneumonia in the compromised host. Medicine (Baltimore). 1977;56:241-254.

• 摘要

39.  Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004;12:657-662.

• 摘要

40.  Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33:465-471.

• 摘要

41.  Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316-322.

• 摘要

42.  Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;12:555-560.

• 摘要

43.  Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011;22:2358-2365.

• 全文
• 摘要

44.  Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol. 2008;6:199-208.

• 摘要

45.  The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987;317:1692-1698.

• 摘要

46.  Pizzo PA, Hanthorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552-558.

• 摘要

47.  Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338-348.

• 摘要

48.  Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;(6):CD003038.

• 全文
• 摘要

49.  Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010 Aug 15;51(4):381-9.

• 摘要

50.  Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;(11):CD005197.

• 全文
• 摘要

51.  Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 2006;37:373-379.

• 摘要

52.  Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006;43:447-459.

• 摘要

53.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections.

• 全文

54.  Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016 Sep;27(suppl 5):v111-v118.

• 全文
• 摘要

55.  Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32:1463-1471.

• 摘要

56.  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis. 1991;163:951-958 (erratum in: J Infect Dis 1991;164:832).

• 摘要

57.  Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597-607.

• 摘要

58.  Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.

• 全文
• 摘要

59.  Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000;18:3699-3706.

• 摘要

60.  Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis. 2011;15:e350-356.

• 摘要

61.  Pizzo PA, Robichaund KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-111.

• 摘要

62.  EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-672.

• 摘要

63.  Cordonnier CP. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042-1051.

• 全文
• 摘要

64.  Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31-38.

• 全文
• 摘要

65.  Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;(10):CD003039.

• 全文
• 摘要

66.  Lyman GH, Kuderer NM. Filgastrim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62:65-78.

• 摘要

67.  Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857-1864.

• 摘要

68.  Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18:539-544.

• 摘要

69.  Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect. 2001;42:120-125.

• 摘要

70.  Darmon M, Azoulay E, Alberti C, et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002;28:1775-1780.

• 摘要

71.  Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247-259.

• 摘要

72.  Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998;158:868-672.

• 全文
• 摘要

73.  Lyman GH, Kuderer NM. Cost-effectiveness of myeloid growth factors in cancer chemotherapy. Curr Hematol Rep. 2003;2:471-479.

• 摘要